Inaba M, Nagashima K, Sakurai Y
Gan. 1984 Jul;75(7):625-30.
In vitro and in vivo cross-resistance to mitoxantrone of two vincristine-resistant sublines of P388 leukemia with different degrees of resistance in vitro was compared with that to adriamycin. A subline with a lower degree of resistance to vincristine exhibited approximately the same responses in vivo to mitoxantrone and adriamycin as the original P388 leukemic cell line, although it was evidently cross-resistant in vitro to these agents. Another subline having a higher degree of resistance to vincristine showed a 25-fold cross-resistance in vitro and gave no response in vivo to adriamycin. With mitoxantrone, on the other hand, this subline was solidly resistant as compared with the sensitive line but still retained significant responsiveness in vivo irrespective of a 150-fold cross-resistance in vitro. These results suggest that cross-resistance on a cellular basis does not necessarily correspond to in vivo cross-resistance. The relationship between in vitro and in vivo cross-resistance is discussed.
比较了体外和体内对米托蒽醌的交叉耐药性,这是针对P388白血病的两个长春新碱耐药亚系,它们在体外具有不同程度的耐药性,同时也与对阿霉素的交叉耐药性进行了比较。一个对长春新碱耐药程度较低的亚系,尽管在体外对这些药物明显存在交叉耐药性,但在体内对米托蒽醌和阿霉素的反应与原始P388白血病细胞系大致相同。另一个对长春新碱耐药程度较高的亚系在体外表现出25倍的交叉耐药性,并且在体内对阿霉素无反应。另一方面,对于米托蒽醌,与敏感系相比,该亚系具有稳固的耐药性,但尽管在体外有150倍的交叉耐药性,在体内仍保留显著的反应性。这些结果表明,基于细胞的交叉耐药性不一定与体内交叉耐药性相对应。文中讨论了体外和体内交叉耐药性之间的关系。